News & Updates
Excerpt from the Press Release: REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the first patient dosed in the Phase 2 TENACITY clinical trial of…
Read More
Excerpt from the Press Release: “We believe that NBTXR3 could have a positive impact for patients with cancer in any case where radiotherapy is a part of the standard of care. Expansion into esophageal cancer represents not only another step toward achieving our goals, it also highlights the ongoing progress of our clinical collaboration agreement…
Read More
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19
Excerpt from the Press Release: BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced it has completed enrollment for its pivotal phase 3 study of lenzilumab for COVID-19. The Company expects to announce top-line…
Read More
Excerpt from the Press Release: “The ability to run a single, highly-sensitive test that detects SARS-CoV-2, Flu A, Flu B, and respiratory syncytial virus provides actionable results and helps to alleviate pressure on the healthcare system,” said Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid. “Xpert® Xpress SARS-CoV-2/Flu/RSV delivers reference lab quality testing in…
Read More
Excerpt from the Article: Images captured with fMRI in a case study reveal the role of the orbitofrontal cortex in patients infected with the virus who experience anosmia and ageusia. Functional MRI (fMRI) has helped increase understanding about the loss of smell and taste that frequently accompany COVID-19 infection. The answer lies in the orbitofrontal…
Read More
Excerpt from the Article: A made-in-Canada vaccine to protect against COVID-19 began human clinical trials Tuesday in Toronto, says the biotechnology company that developed the vaccine. Toronto-based Providence Therapeutics said three shots will be given to 60 adult volunteers at a clinical trial site in Toronto in the first phase of the trial on Tuesday. Fifteen of…
Read More
Excerpt from the Article: LA JOLLA, CA—A big question on people’s minds these days: how long does immunity to SARS-CoV-2 last following infection? Now a research team from La Jolla Institute for Immunology (LJI), The University of Liverpool and the University of Southampton has uncovered an interesting clue. Their new study suggests that people with…
Read More
Excerpt from the Press Release: PHILADELPHIA—Patients with inactive cancer and not currently undergoing treatments also face a significantly higher risk of severe illness from COVID-19, a new study from Penn Medicine published online today in JNCI Cancer Spectrum shows. Past reports have established an increased risk of severe disease and death for sick or hospitalized…
Read More
On January 21st, we held our first Ask Us Anything in Clinical Research Virtual networking meeting for the new year! Heather and I were joined by our guest speaker, Pearl Mensah of Pilatus Comparator Solutions for this exciting meeting. We’ve had 10 months of experience marketing and selling remotely. We’ve seen what worked, and what’s…
Read More
Excerpt from the Article: It is possible to increase the specificity of low-dose CT (LDCT) lung cancer screening programs without chipping away at sensitivity – all it takes is folding artificial intelligence (AI) in with Lung-RADS. That capability is based on the development of a lung nodule management system, created by investigators from the University…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?